Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
United European Gastroenterology Journal · 2025
DOI: 10.1002/ueg2.70055 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von Nicola Pugliese und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. Hauptthemen laut MEDLINE: Weight Loss, Fatty Liver. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, Heal Italia project PE00000019 CUP B73C22001250006, Italian PNRR-MAD-2022-12375656.
Abstract (Originalsprache)
Background and Aims Weight loss is an effective therapeutic strategy for patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). This study aimed to identify factors that predict relevant weight loss, defined as at least 7% of initial body weight, in MASLD outpatients.
Method
We retrospectively included all MASLD patients referred to four Italian tertiary centers between January 2019 and December 2021. Patients received lifestyle modification advice according to current guidelines, with reassessment of anthropometric measures after 18–24 months.
Results
A total of 897 patients were included. The majority were male (57%) with a mean age of 61.6 ± 13.3 years and a mean baseline body mass index (BMI) of 30.3 ± 4.5 kg/m 2 . Comorbidities included type 2 diabetes (T2D; 36%), arterial hypertension (54.7%) and dyslipidemia (55.2%). Over a median observation period of 21 months, 164 (18.3%) patients achieved relevant weight loss. Multiple adjusted regression analysis identified baseline BMI between 30 and 34.9 kg/m 2 (odds ratio, OR = 1.95, 95% confidence interval, CI: 1.30–2.95) or ≥ 35 kg/m 2 (OR = 2.08, 95% CI: 1.21–3.57), use of GLP‐1 agonists for T2D (OR 1.85, 95% CI: 1.19–3.80), bilirubin levels ≥ 1.2 mg/dL (OR 2.12, 95% CI: 1.29–3.51) nutritionist support (OR 2.04, 95% CI: 1.12–3.71) and liver stiffness measurement (LSM) ≥ 10 kPa (OR 1.70, 95% CI: 1.07–2.70) as independent predictors of relevant weight loss.
Conclusions
Baseline BMI ≥ 30 kg/m 2 , use of GLP‐1 agonists, elevated bilirubin levels, support from a nutritionist and LSM ≥ 10 kPa are significant predictors of relevant weight loss in MASLD patients. These findings underscore the importance of personalized interventions in MASLD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
- Hepatology Unit, San Giuseppe Hospital, Milan, Italy.
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
- Unit of Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
ORCID-Profile: Rosa Lombardi, Salvatore Petta
Förderung
- Ministero dell'Istruzione, dell'Università e della Ricerca
- Heal Italia project PE00000019 CUP B73C22001250006
- Italian PNRR-MAD-2022-12375656
- PRIN 2022 2022L273C9
- RF-2021-12372399
- Ministero dell’Istruzione, dell’Università e della Ricerca
Zitieren
APA
Pugliese, N., Arcari, I., Cerini, F., Lombardi, R., Turati, F., Pennisi, G., Soleri, M., Rocchetto, S., De Deo, D., Sagasta, M., Masetti, C., Fracanzani, A. L., Petta, S., La Vecchia, C., Viganò, M., & Aghemo, A. (2025). Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70055
Vancouver
Pugliese N, Arcari I, Cerini F, Lombardi R, Turati F, Pennisi G, et al. Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.70055
BibTeX
@article{Pugliese2025,
author = {Pugliese, Nicola and Arcari, Ivan and Cerini, Federica and Lombardi, Rosa and Turati, Federica and Pennisi, Grazia and Soleri, Matteo and Rocchetto, Simone and De Deo, Diletta and Sagasta, Michele and Masetti, Chiara and Fracanzani, Anna Ludovica and Petta, Salvatore and La Vecchia, Carlo and Viganò, Mauro and Aghemo, Alessio},
title = {Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {United European Gastroenterology Journal},
year = {2025},
doi = {10.1002/ueg2.70055}
}
EUVIMED